The bronchodilator effects of Roflumilast “a selective phosphodiesterase type-4 (PDE4)”
inhibitor studied in this experimental protocol. The spiral strips of isolated guinea-pig …

Roflumilast is an oral, add‐on option for treating patients with severe COPD and frequent
exacerbations despite optimal therapy with inhaled drugs. The present study focused on …

Asthma and chronic obstructive pulmonary disease (COPD) is characterized by progressive
deterioration of lung function and is a leading cause of morbidity and mortality in the world …

Background: Roflumilast is an option for treating patients with severe COPD and frequent
exacerbations despite optimal therapy with inhaled drugs. The present study focused on …

Roflumilast is a selective phosphodiesterase (PDE) 4 inhibitor with a range of anti-
inflammatory properties and potential for treatment of inflammatory disease. The therapeutic …

With the aim of studying their in vitro and in vivo pharmacokinetics, new chromatographic
methods were developed for the determination of three new roflumilast synthetic analogs (I …

We have investigated the bronchodilator and anti-inflammatory properties of roflumilast (3-
cyclopropylmethoxy-4-difluoromethoxy-N-[3, 5-dichloropyrid-4-yl]-benzamide), a novel …

Introduction: Roflumilast is a selective PDE4 inhibitor recently approved for oral, once-daily
treatment of severe chronic obstructive pulmonary disease (COPD). Clinical trials have …

Abstract Phosphodiesterase-4 inhibitors (PDE4) are of great interest for the treatment of
airway inflammatory diseases due to its broad anti-inflammatory effects. Roflumilast is a …

Roflumilast is an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor with anti-
inflammatory activity. We compared the anti-inflammatory effects of roflumilast with those of …